These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

402 related items for PubMed ID: 19808126

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Lercanidipine in the treatment of hypertension.
    Beckey C, Lundy A, Lutfi N.
    Ann Pharmacother; 2007 Mar; 41(3):465-73. PubMed ID: 17341540
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Calcium channel blockers for people with chronic kidney disease requiring dialysis.
    Mugendi GA, Mutua FM, Natale P, Esterhuizen TM, Strippoli GF.
    Cochrane Database Syst Rev; 2020 Oct 01; 10(10):CD011064. PubMed ID: 33000470
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Improved tolerability of the dihydropyridine calcium-channel antagonist lercanidipine: the lercanidipine challenge trial.
    Borghi C, Prandin MG, Dormi A, Ambrosioni E, Study Group of the Regional Unit of the Italian Society of Hypertension.
    Blood Press Suppl; 2003 May 01; 1():14-21. PubMed ID: 12800983
    [Abstract] [Full Text] [Related]

  • 7. Tolerability of long-term treatment with lercanidipine versus amlodipine and lacidipine in elderly hypertensives.
    Leonetti G, Magnani B, Pessina AC, Rappelli A, Trimarco B, Zanchetti A, COHORT Study Group.
    Am J Hypertens; 2002 Nov 01; 15(11):932-40. PubMed ID: 12441211
    [Abstract] [Full Text] [Related]

  • 8. Lercanidipine in hypertension.
    Borghi C.
    Vasc Health Risk Manag; 2005 Nov 01; 1(3):173-82. PubMed ID: 17319103
    [Abstract] [Full Text] [Related]

  • 9. Tolerability of high doses of lercanidipine versus high doses of other dihydropyridines in daily clinical practice: the TOLERANCE Study.
    Barrios V, Escobar C, de la Figuera M, Llisterri JL, Honorato J, Segura J, Calderón A.
    Cardiovasc Ther; 2008 Nov 01; 26(1):2-9. PubMed ID: 18466416
    [Abstract] [Full Text] [Related]

  • 10. Peripheral edema associated with calcium channel blockers: incidence and withdrawal rate--a meta-analysis of randomized trials.
    Makani H, Bangalore S, Romero J, Htyte N, Berrios RS, Makwana H, Messerli FH.
    J Hypertens; 2011 Jul 01; 29(7):1270-80. PubMed ID: 21558959
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Lercanidipine : a review of its efficacy in the management of hypertension.
    Bang LM, Chapman TM, Goa KL.
    Drugs; 2003 Jul 01; 63(22):2449-72. PubMed ID: 14609358
    [Abstract] [Full Text] [Related]

  • 13. [Lercanidipine, a third generation calcium antagonist. Which advantages?].
    Meier P, Burnier M.
    Rev Med Suisse; 2006 Sep 13; 2(78):2047-50, 2052-3. PubMed ID: 17019840
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and tolerability of lercanidipine in mild to moderate hypertension among Asians of different ethnic groups.
    Chia YC, Yeoh ES, Ng CJ, Khoo EM, Chua CT.
    Singapore Med J; 2009 May 13; 50(5):500-5. PubMed ID: 19495520
    [Abstract] [Full Text] [Related]

  • 15. Comparative effect of lercanidipine, felodipine, and nifedipine GITS on blood pressure and heart rate in patients with mild to moderate arterial hypertension: the Lercanidipine in Adults (LEAD) Study.
    Romito R, Pansini MI, Perticone F, Antonelli G, Pitzalis M, Rizzon P.
    J Clin Hypertens (Greenwich); 2003 May 13; 5(4):249-53. PubMed ID: 12939564
    [Abstract] [Full Text] [Related]

  • 16. Time course for blood pressure lowering of dihydropyridine calcium channel blockers.
    Ghamami N, Chiang SH, Dormuth C, Wright JM.
    Cochrane Database Syst Rev; 2014 Aug 31; 2014(8):CD010052. PubMed ID: 25173808
    [Abstract] [Full Text] [Related]

  • 17. Patient adherence and the choice of antihypertensive drugs: focus on lercanidipine.
    Pruijm MT, Maillard MP, Burnier M.
    Vasc Health Risk Manag; 2008 Aug 31; 4(6):1159-66. PubMed ID: 19337529
    [Abstract] [Full Text] [Related]

  • 18. Emerging data on calcium-channel blockers: the COHORT study.
    Zanchetti A.
    Clin Cardiol; 2003 Feb 31; 26(2 Suppl 2):II17-20. PubMed ID: 12622322
    [Abstract] [Full Text] [Related]

  • 19. Renal protection with calcium antagonists: the role of lercanidipine.
    Burnier M.
    Curr Med Res Opin; 2013 Dec 31; 29(12):1727-35. PubMed ID: 24069902
    [Abstract] [Full Text] [Related]

  • 20. Quantification of leg oedema in postmenopausal hypertensive patients treated with lercanidipine or amlodipine.
    Lund-Johansen P, Stranden E, Helberg S, Wessel-Aas T, Risberg K, Rønnevik PK, Istad H, Madsbu S.
    J Hypertens; 2003 May 31; 21(5):1003-10. PubMed ID: 12714876
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.